Sign inJoin waitlistJoin the waitlist

Bita Fakhri

Director of the CLL Clinical Trial Portfolio · Stanford

Credentials: · · · · · · ·

History

School of Medicine
2026–Present
Stanford University School of Medicine
Present

Washington University School of Medicine
Until 2018
Boston University Medical Center
Until 2015
Iran University of Medical Sciences
2009

Research

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
The Lancet · 2021 · 391 citations
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
New England Journal of Medicine · 2023 · 204 citations
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study
The Lancet · 2023 · 179 citations

Chaitra Ujjani
9 papers
Jonathon Cohen
9 papers
CC
Catherine Coombs
8 papers · 3 as a fellow
Jennifer Brown
8 papers
Jennifer Woyach
8 papers
Weiyun Ai
8 papers
Brian Hill
7 papers
DT
Donald Tsai
7 papers
Nicole Lamanna
7 papers
Shuo Ma
7 papers
Charalambos Andreadis
6 papers
Joanna Rhodes
6 papers · 1 as a fellow

Clinical trials

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Site PI · Recruiting · Phase 2
Loxo Oncology, Inc.
2025–2028
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Site PI · Recruiting · Phase 2
Mayo Clinic
2023–2027
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Site PI · Recruiting · Phase 3
Loxo Oncology, Inc.
2022–2028